Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market Size, Demand, Type & Applications, Market Status And Forecasts To 2026

Recurrence of
multiple myeloma has been a highly prevalent health condition, which
requires novel and effective immunotherapeutic treatment. According
to Leukemia Research by Elsevier, as of 2014, the incidence of
multiple myeloma is estimated to be around 120,000 cases per year,
with a global prevalence of over one million cases. B-cell maturation
antigen (BCMA), is a cell surface protein that is expressed on the
malignant plasma cells. This cell surface protein has emerged as a
very selective antigen targeted therapy for the treatment of multiple
myeloma. BCMA targeted therapies actively involve three major types
of immunotherapies on the basis of product class namely, chimeric
antigen receptor T-cells (CAR T Cells), bispecific antibodies, and
antibody drug conjugates (ADCs). These advanced therapies are
expected to improve the survival rate of multiple myeloma patients.

Request For The
Sample Copy Of This Business Report:
https://www.coherentmarketinsights.com/insight/request-sample/190

Market
Dynamics

Increasing
prevalence of multiple myeloma is expected to favor the B-cell
maturation antigen (BCMA) targeted therapies market worldwide.
According to the American Cancer Society, U.S., in 2016, the lifetime
risk for multiple myeloma was around 1 in 143 people, with an
estimated 30,280 adults (17,490 men and 12,790 women) diagnosed with
multiple myeloma. The mortality rate of the disease was estimated to
be 12,590 (6,660 men and 5,930 women) in 2016. Key players are
actively involved in the development of immunotherapies targeting
BCMA for the treatment of multiple myeloma, the demand for which is
expected to increase, This in turn, is expected to boost development
of novel treatments for relapsed or refractory myeloma. Furthermore,
patients undergoing existing drug therapies are prone to the risk of
relapse. Hence, B-cell maturation antigen targeted therapy, which
primarily addresses this concern is expected to gain rapid traction.

Market
Taxonomy

This report segments
the global B-cell maturation antigen (BCMA) targeted therapies market
on the basis on product type, indication, and regions. On the basis
of product type, the market is segmented into antibody drug
conjugates, CAR-T cells, bispecific antibodies. On the basis of
indication, the market is segmented into acute lymphoblastic leukemia
and multiple myeloma.

Key Features
of the Study:

Detailed
Segmentation:

High unmet
needs by the recurring cases of multiple myeloma is expected to drive
growth of the B-cell maturation Antigen (BCMA) targeted therapies
market

The patients
undergoing chemotherapy and radiation therapy are at high risk of
recurrence of cancer as they develop resistance to these therapy. At
present there are no treatment options are available for patients
with recurrent cancer and hence the BCMA targeted therapies provides
breakthrough therapeutic options for the treatment of relapsed or
refractory multiple myeloma and will also cater to the current unmet
needs for the treatment of relapsed or refractory myeloma, where the
existing treatment modalities have proved to be clinically
inefficient.

Key players
operating in the development of B-cell maturation antigen (BCMA)
targeted therapies market are Celgene Corporation, GlaxoSmithKline
plc, Novartis AG, Juno Therapeutics, Gilead Sciences. Inc., Amgen
Inc., Affimed N.V, Poseida Therapeutics, Inc., and Autolus Ltd.

Click To Read
More On Global
B-cell Maturation Antigen (BCMA) Targeted Therapies Market

About
Coherent Market Insights:

Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.